📣 Help Shape the Future of UKRI's Gateway to Research (GtR)

We're improving UKRI's Gateway to Research and are seeking your input! If you would be interested in being interviewed about the improvements we're making and to have your say about how we can make GtR more user-friendly, impactful, and effective for the Research and Innovation community, please email gateway@ukri.org.

Enasidenib vs conventional care in older patients with late-stage mutant-IDH2 relapsed/refractory AML: a randomized phase 3 trial. (2023)

First Author: De Botton S

Attributed to: Identification, characterisation and therapeutic targeting of leukaemic stem/propagating cells in Acute Myeloid Leukaemia funded by MRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1182/blood.2021014901

PubMed Identifier: 35714312

Publication URI: http://europepmc.org/abstract/MED/35714312

Type: Journal Article/Review

Volume: 141

Parent Publication: Blood

Issue: 2

ISSN: 0006-4971